{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:52:53Z","timestamp":1788839573693,"version":"build-2803163510"},"reference-count":29,"publisher":"American Association for Cancer Research (AACR)","issue":"12","license":[{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA008748"],"award-info":[{"award-number":["P50 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Preclinical studies show that activation of AMP kinase by phenformin can augment the cytotoxic effect and RAF inhibitors in BRAF V600-mutated melanoma. We conducted a phase Ib dose-escalation trial of phenformin with standard dose dabrafenib\/trametinib in patients with metastatic BRAF V600-mutated melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental Design:<\/jats:title>\n                    <jats:p>We used a 3+3 dose-escalation design which explored phenformin doses between 50 and 200 mg twice daily. Patients also received standard dose dabrafenib\/trametinib. We measured phenformin pharmacokinetics and assessed the effect of treatment on circulating myeloid-derived suppressor cells (MDSC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 18 patients were treated at dose levels ranging from 50 to 200 mg twice daily. The planned dose-escalation phase had to be cancelled because of the COVID 19 pandemic. The most common toxicities were nausea\/vomiting; there were two cases of reversible lactic acidosis. Responses were seen in 10 of 18 patients overall (56%) and in 2 of 8 patients who had received prior therapy with RAF inhibitor. Pharmacokinetic data confirmed drug bioavailability. MDSCs were measured in 7 patients treated at the highest dose levels and showed MDSC levels declined on study drug in 6 of 7 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>We identified the recommended phase II dose of phenformin as 50 mg twice daily when administered with dabrafenib\/trametinib, although some patients will require short drug holidays. We observed a decrease in MDSCs, as predicted by preclinical studies, and may enhance immune recognition of melanoma cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This is the first trial using phenformin in combination with RAF\/MEK inhibition in patients with BRAF V600-mutated melanoma. This is a novel strategy, based on preclinical data, to increase pAMPK while blocking the MAPK pathway in melanoma. Our data provide justification and a recommended dose for a phase II trial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0296","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T08:47:35Z","timestamp":1699260455000},"page":"2447-2454","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1618-0811","authenticated-orcid":true,"given":"Paul B.","family":"Chapman","sequence":"first","affiliation":[{"name":"1Department of Medicine, Weill Cornell Medicine, New York, New York."},{"name":"2Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8753-9783","authenticated-orcid":true,"given":"Mark","family":"Klang","sequence":"additional","affiliation":[{"name":"3Research Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3367-7961","authenticated-orcid":true,"given":"Michael A.","family":"Postow","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Weill Cornell Medicine, New York, New York."},{"name":"2Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-4412","authenticated-orcid":true,"given":"Alexander Noor","family":"Shoushtari","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Weill Cornell Medicine, New York, New York."},{"name":"2Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":true,"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"4Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6718-2222","authenticated-orcid":true,"given":"Jedd D.","family":"Wolchok","sequence":"additional","affiliation":[{"name":"2Weill Cornell Medical College, New York, New York."},{"name":"5Ludwig Institute for Cancer Research, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1518-5111","authenticated-orcid":true,"given":"Taha","family":"Merghoub","sequence":"additional","affiliation":[{"name":"2Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3284-1408","authenticated-orcid":true,"given":"Sadna","family":"Budhu","sequence":"additional","affiliation":[{"name":"2Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6360-849X","authenticated-orcid":true,"given":"Phillip","family":"Wong","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Weill Cornell Medicine, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9087-0012","authenticated-orcid":true,"given":"Margaret K.","family":"Callahan","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Weill Cornell Medicine, New York, New York."},{"name":"2Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0998-7177","authenticated-orcid":true,"given":"Bin","family":"Zheng","sequence":"additional","affiliation":[{"name":"4Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5882-0189","authenticated-orcid":true,"given":"Jonathan","family":"Zippin","sequence":"additional","affiliation":[{"name":"2Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,12,4]]},"reference":[{"key":"2023120414034888000_bib1","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ccr.2012.10.009","article-title":"Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas","volume":"22","author":"Lito","year":"2012","journal-title":"Cancer Cell"},{"key":"2023120414034888000_bib2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ccell.2014.10.017","article-title":"Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged","volume":"26","author":"Chapman","year":"2014","journal-title":"Cancer Cell"},{"key":"2023120414034888000_bib3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","article-title":"Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF","volume":"23","author":"Haq","year":"2013","journal-title":"Cancer Cell"},{"key":"2023120414034888000_bib4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/onc.2016.198","article-title":"Metabolic rewiring in melanoma","volume":"36","author":"Ratnikov","year":"2017","journal-title":"Oncogene"},{"key":"2023120414034888000_bib5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2159-8290.CD-13-0440","article-title":"Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis","volume":"4","author":"Parmenter","year":"2014","journal-title":"Cancer Discov"},{"key":"2023120414034888000_bib6","doi-asserted-by":"crossref","first-page":"e02242","DOI":"10.7554\/eLife.02242","article-title":"Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis","volume":"3","author":"Wheaton","year":"2014","journal-title":"Elife"},{"key":"2023120414034888000_bib7","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.trecan.2021.03.001","article-title":"Therapeutic repurposing of biguanides in cancer","volume":"7","author":"Zhao","year":"2021","journal-title":"Trends Cancer"},{"key":"2023120414034888000_bib8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.molcel.2013.08.044","article-title":"Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation","volume":"52","author":"Shen","year":"2013","journal-title":"Mol Cell"},{"key":"2023120414034888000_bib9","doi-asserted-by":"crossref","first-page":"18226","DOI":"10.1073\/pnas.1317577110","article-title":"Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma","volume":"110","author":"Yuan","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023120414034888000_bib10","doi-asserted-by":"crossref","first-page":"e0133743","DOI":"10.1371\/journal.pone.0133743","article-title":"Esters of bendamustine are by far more potent cytotoxic agents than the parent compound against human sarcoma and carcinoma cells","volume":"10","author":"Huber","year":"2015","journal-title":"PLoS One"},{"key":"2023120414034888000_bib11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/pcmr.12576","article-title":"Metformin monotherapy in melanoma: a pilot, open-label, prospective, and multicentric study indicates no benefit","volume":"30","author":"Montaudi\u00e9","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"2023120414034888000_bib12","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.jid.2017.03.033","article-title":"Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma","volume":"137","author":"Kim","year":"2017","journal-title":"J Invest Dermatol"},{"key":"2023120414034888000_bib13","first-page":"183","article-title":"A comparison of phenformin and metformin in the treatment of maturity onset diabetes","volume":"3","author":"Cairns","year":"1977","journal-title":"Diabete Metab"},{"key":"2023120414034888000_bib14","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2337\/diab.9.3.220","article-title":"Phenformin in the management of diabetes mellitus \u2013 general clinical concepts","volume":"9","author":"Goldner","year":"1960","journal-title":"Diabetes"},{"key":"2023120414034888000_bib15","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/bmj.1.5697.660","article-title":"Phenformin in insulin-dependent diabetics","volume":"1","author":"Bloom","year":"1970","journal-title":"Brit Med J"},{"key":"2023120414034888000_bib16","first-page":"20967","article-title":"Phenformin hydrochloride: withdrawl of approval of new drug application; final decision","volume":"44","author":"Kennedy","year":"1979","journal-title":"Fed Regist"},{"key":"2023120414034888000_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1042\/cs0580153","article-title":"Correlation of plasma phenformin concentration with metabolic effects in normal subjects","volume":"58","author":"Nattrass","year":"1980","journal-title":"Clin Sci"},{"key":"2023120414034888000_bib18","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/clpt.1987.55","article-title":"Plasma biguanide levels are correlated with metabolic effects in diabetic patients","volume":"41","author":"Marchetti","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"2023120414034888000_bib19","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/j.1552-4604.1975.tb02367.x","article-title":"Pharmacokinetics of phenformin in man","volume":"15","author":"Alkalay","year":"1975","journal-title":"J Clin Pharmacol"},{"key":"2023120414034888000_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1158\/2326-6066.CIR-13-0068","article-title":"Enhancement of tumor-reactive cytotoxic CD4+ T-cell responses after ipilimumab treatment in four advanced melanoma patientsenhancement of cytotoxic CD4+ T-cell response after ipilimumab treatment","volume":"1","author":"Kitano","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"2023120414034888000_bib21","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2326-6066.CIR-14-0013","article-title":"Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes","volume":"2","author":"Kitano","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"2023120414034888000_bib22","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2337\/diab.30.8.644","article-title":"Defective hydroxylation of phenformin as a determinant of drug toxicity","volume":"30","author":"Bosisio","year":"1981","journal-title":"Diabetes"},{"key":"2023120414034888000_bib23","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1158\/0008-5472.CAN-16-1755","article-title":"Myeloid cells that impair immunotherapy are restored in melanomas with acquired resistance to BRAF inhibitors","volume":"77","author":"Steinberg","year":"2017","journal-title":"Cancer Res"},{"key":"2023120414034888000_bib24","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/s41467-022-29000-5","article-title":"Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"2023120414034888000_bib25","doi-asserted-by":"crossref","first-page":"e87705","DOI":"10.1371\/journal.pone.0087705","article-title":"Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab","volume":"9","author":"Tarhini","year":"2014","journal-title":"PLoS One"},{"key":"2023120414034888000_bib26","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1158\/1078-0432.CCR-15-3104","article-title":"Clinical significance of circulating CD33+CD11b+HLA-DR- myeloid cells in patients with stage IV melanoma treated with ipilimumab","volume":"22","author":"Sade-Feldman","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2023120414034888000_bib27","doi-asserted-by":"crossref","first-page":"e1494113","DOI":"10.1080\/2162402X.2018.1494113","article-title":"Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: a meta-analysis of 40 studies","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"2023120414034888000_bib28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","article-title":"Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials","volume":"29","author":"Yap","year":"2023","journal-title":"Nat Med"},{"key":"2023120414034888000_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41591-022-02129-y","article-title":"Time to hit pause on mitochondria-targeting cancer therapies","volume":"29","author":"Zhang","year":"2023","journal-title":"Nat Med"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0296\/3380712\/crc-23-0296.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/12\/2447\/3388041\/crc-23-0296.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/12\/2447\/3388041\/crc-23-0296.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T09:04:10Z","timestamp":1701680650000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/12\/2447\/731479\/Phase-Ib-Trial-of-Phenformin-in-Patients-with-V600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,4]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,4]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0296","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.24721662","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24721671.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24721671","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24721677","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24721665","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24721665.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24721653","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24721674","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24721659","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24721680.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24721656.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24721668","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24721656","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24721659.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24721653.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24721662.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24721677.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24721674.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24721668.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24721680","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6963879.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6963879","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,4]]}}}